Source: International Congress 2015 – Connective tissue disorders
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Eda Boerner (Haan, Germany), Eda B. Boerner, Thomas E. Wessendorf, Shinichiro Ohshimo, Ulrich Costabel, Francesco Bonella. Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD). Eur Respir J 2015; 46: Suppl. 59, 3803

Member's Comments

No comment yet.

Related content which might interest you: Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis Source: International Congress 2016 – Connective tissue disorders Year: 2016 Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Detection of anti DFS70 antibodies in patients with interstitial lung disease (ILD) with and without connective tissue disease (CTD) Source: International Congress 2016 – Connective tissue disorders Year: 2016 Predicting progression of RA-ILD using anti-CCP Source: International Congress 2015 – Connective tissue disorders Year: 2015 Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy}, Source: Eur Respir J 2012; 40: 641-648 Year: 2012 Idiopathic non-specific interstitial pneumonia (iNSIP): do the patients develop connective tissue disease (CTD) during follow-up? Source: International Congress 2016 – Connective tissue disorders Year: 2016 Are there any clinical differences between SSc-ILD and UCTD suspected of SSc -ILD? Source: International Congress 2015 – Connective tissue disorders Year: 2015 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Chemical exposure triggering connective tissue disease with lung involvement Source: International Congress 2015 – Occupational disease: clinical cases and series Year: 2015 Usefulness of a myositis antibody immunoblot in diagnosis of connective tissue disease (CTD) related interstitial lung disease (ILD) Source: International Congress 2014 – ILDs 4 Year: 2014 What if my lung-dominant connective tissue disease (LD-CTD) patient eventually met criteria for a definite CTD: The role of prognosis! Source: International Congress 2015 – Connective tissue disorders Year: 2015 Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease Source: International Congress 2015 – Connective tissue disorders Year: 2015